Vanguard Capital Management
TERN

Vanguard Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Vanguard Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,355,482
Closed -$230M – 4149
2026
Q1 		$230M Buy
+4,355,482
New +$179M 0.01% 992

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Capital Management's TERN Position: Q2 2026 in Review

Vanguard Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 4,355,482 shares — an estimated $230M sold.

Vanguard Capital Management first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $230M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Vanguard Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Capital Management sold 4,355,482 Terns Pharmaceuticals shares in Q2 2026, an estimated $230M.
  • Vanguard Capital Management first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Capital Management's Terns Pharmaceuticals position peaked at $230M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.